HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cross-reactivity and tolerability of imipenem in patients with delayed-type, cell-mediated hypersensitivity to beta-lactams.

AbstractBACKGROUND:
Administration of imipenem-cilastatin to patients with IgE-mediated hypersensitivity to beta-lactams has always been considered potentially harmful. Recent studies have demonstrated the tolerability of carbapenems (imipenem-cilastatin and meropenem) in patients with IgE-mediated hypersensitivity to beta-lactams; there are no studies on this topic regarding patients with cell-mediated allergy to beta-lactams. The aim of this study is to assess cross-reactivity and tolerability of imipenem in patients with cell-mediated allergy to beta-lactams.
METHODS:
From our database we selected 73 patients with cell-mediated allergy to beta-lactams, diagnosed by means of immediate-type skin tests, delayed reading intradermal tests, patch tests and detection of specific IgE. Patients with negative patch tests with imipenem-cilastatin underwent an intramuscular test dosing.
RESULTS:
Our patients had a total of 94 nonimmediate reactions to penicillins. All patients had positive patch tests and/or delayed reading intradermal tests for at least one of the penicillin reagent tested and negative immediate-type skin tests and specific IgE. Four patients out of 73 had a positive patch tests to at least one penicillin reagent and imipenem-cilastatin showing cross-reactivity. Sixty-four patients underwent the imipenem-cilastatin intramuscular test dosing and none of them had a clinical reaction.
CONCLUSIONS:
Our rate of cross-reactivity between imipenem-cilastatin and other beta-lactams was 5.5%. This result is different from previous findings and this may be explained by the fact that we investigated patients with cell-mediated allergy to beta-lactams. Patients with cell-mediated allergy to beta-lactams should undergo patch tests and a tolerance challenge test before treatment with imipenem-cilastatin.
AuthorsD Schiavino, E Nucera, C Lombardo, M Decinti, L Pascolini, G Altomonte, A Buonomo, G Patriarca
JournalAllergy (Allergy) Vol. 64 Issue 11 Pg. 1644-8 (Nov 2009) ISSN: 1398-9995 [Electronic] Denmark
PMID19392998 (Publication Type: Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Drug Combinations
  • beta-Lactams
  • Cilastatin
  • Imipenem
  • Cilastatin, Imipenem Drug Combination
Topics
  • Adult
  • Anti-Bacterial Agents (administration & dosage, adverse effects, immunology)
  • Cilastatin (administration & dosage, adverse effects, immunology)
  • Cilastatin, Imipenem Drug Combination
  • Cross Reactions
  • Drug Combinations
  • Drug Hypersensitivity (diagnosis, etiology, immunology)
  • Drug Tolerance
  • Female
  • Humans
  • Hypersensitivity, Delayed (chemically induced, immunology)
  • Imipenem (administration & dosage, adverse effects, immunology)
  • Immunity, Cellular
  • Male
  • Middle Aged
  • Patch Tests
  • Skin Tests
  • beta-Lactams (administration & dosage, adverse effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: